226 related articles for article (PubMed ID: 35234147)
1. Fast fragment- and compound-screening pipeline at the Swiss Light Source.
Kaminski JW; Vera L; Stegmann DP; Vering J; Eris D; Smith KML; Huang CY; Meier N; Steuber J; Wang M; Fritz G; Wojdyla JA; Sharpe ME
Acta Crystallogr D Struct Biol; 2022 Mar; 78(Pt 3):328-336. PubMed ID: 35234147
[TBL] [Abstract][Full Text] [Related]
2. Fast fragment and compound screening pipeline at the Swiss Light Source.
Stegmann DP; Steuber J; Fritz G; Wojdyla JA; Sharpe ME
Methods Enzymol; 2023; 690():235-284. PubMed ID: 37858531
[TBL] [Abstract][Full Text] [Related]
3. AutoDrug: fully automated macromolecular crystallography workflows for fragment-based drug discovery.
Tsai Y; McPhillips SE; González A; McPhillips TM; Zinn D; Cohen AE; Feese MD; Bushnell D; Tiefenbrunn T; Stout CD; Ludaescher B; Hedman B; Hodgson KO; Soltis SM
Acta Crystallogr D Biol Crystallogr; 2013 May; 69(Pt 5):796-803. PubMed ID: 23633588
[TBL] [Abstract][Full Text] [Related]
4. Recent progress in robot-based systems for crystallography and their contribution to drug discovery.
Ferrer JL; Larive NA; Bowler MW; Nurizzo D
Expert Opin Drug Discov; 2013 Jul; 8(7):835-47. PubMed ID: 23656378
[TBL] [Abstract][Full Text] [Related]
5. HEIDI: an experiment-management platform enabling high-throughput fragment and compound screening.
Metz A; Stegmann DP; Panepucci EH; Buehlmann S; Huang CY; McAuley KE; Wang M; Wojdyla JA; Sharpe ME; Smith KML
Acta Crystallogr D Struct Biol; 2024 May; 80(Pt 5):328-335. PubMed ID: 38606665
[TBL] [Abstract][Full Text] [Related]
6. Structure-guided fragment-based drug discovery at the synchrotron: screening binding sites and correlations with hotspot mapping.
Thomas SE; Collins P; James RH; Mendes V; Charoensutthivarakul S; Radoux C; Abell C; Coyne AG; Floto RA; von Delft F; Blundell TL
Philos Trans A Math Phys Eng Sci; 2019 Jun; 377(2147):20180422. PubMed ID: 31030650
[TBL] [Abstract][Full Text] [Related]
7. Workflow and Tools for Crystallographic Fragment Screening at the Helmholtz-Zentrum Berlin.
Wollenhaupt J; Barthel T; Lima GMA; Metz A; Wallacher D; Jagudin E; Huschmann FU; Hauß T; Feiler CG; Gerlach M; Hellmig M; Förster R; Steffien M; Heine A; Klebe G; Mueller U; Weiss MS
J Vis Exp; 2021 Mar; (169):. PubMed ID: 33749678
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive approach to X-ray crystallography for drug discovery at a synchrotron facility - The example of Diamond Light Source.
Mazzorana M; Shotton EJ; Hall DR
Drug Discov Today Technol; 2020 Dec; 37():83-92. PubMed ID: 34895658
[TBL] [Abstract][Full Text] [Related]
9. SDU - software for high-throughput automated data collection at the Swiss Light Source.
Smith KML; Panepucci E; Kaminski JW; Aumonier S; Huang CY; Eris D; Buntschu D; Meier N; Glettig W; McAuley KE; Wang M; Sharpe ME; Wojdyla JA
J Synchrotron Radiat; 2023 May; 30(Pt 3):538-545. PubMed ID: 37042663
[TBL] [Abstract][Full Text] [Related]
10. Acoustic methods for high-throughput protein crystal mounting at next-generation macromolecular crystallographic beamlines.
Roessler CG; Kuczewski A; Stearns R; Ellson R; Olechno J; Orville AM; Allaire M; Soares AS; Héroux A
J Synchrotron Radiat; 2013 Sep; 20(Pt 5):805-8. PubMed ID: 23955046
[TBL] [Abstract][Full Text] [Related]
11. Crystallographic fragment screening in academic cancer drug discovery.
Martin MP; Endicott JA; Noble MEM; Tatum NJ
Methods Enzymol; 2023; 690():211-234. PubMed ID: 37858530
[TBL] [Abstract][Full Text] [Related]
12. Counting on Fragment Based Drug Design Approach for Drug Discovery.
Kashyap A; Singh PK; Silakari O
Curr Top Med Chem; 2018; 18(27):2284-2293. PubMed ID: 30499406
[TBL] [Abstract][Full Text] [Related]
13. Automation of macromolecular crystallography beamlines.
Arzt S; Beteva A; Cipriani F; Delageniere S; Felisaz F; Förstner G; Gordon E; Launer L; Lavault B; Leonard G; Mairs T; McCarthy A; McCarthy J; McSweeney S; Meyer J; Mitchell E; Monaco S; Nurizzo D; Ravelli R; Rey V; Shepard W; Spruce D; Svensson O; Theveneau P
Prog Biophys Mol Biol; 2005 Oct; 89(2):124-52. PubMed ID: 15910915
[TBL] [Abstract][Full Text] [Related]
14. Designing a diverse high-quality library for crystallography-based FBDD screening.
Tounge BA; Parker MH
Methods Enzymol; 2011; 493():3-20. PubMed ID: 21371585
[TBL] [Abstract][Full Text] [Related]
15. Fragment-based screening by protein crystallography: successes and pitfalls.
Chilingaryan Z; Yin Z; Oakley AJ
Int J Mol Sci; 2012 Oct; 13(10):12857-79. PubMed ID: 23202926
[TBL] [Abstract][Full Text] [Related]
16. Advantages of crystallographic fragment screening: functional and mechanistic insights from a powerful platform for efficient drug discovery.
Patel D; Bauman JD; Arnold E
Prog Biophys Mol Biol; 2014; 116(2-3):92-100. PubMed ID: 25117499
[TBL] [Abstract][Full Text] [Related]
17. Rapid-access, high-throughput synchrotron crystallography for drug discovery.
Wasserman SR; Koss JW; Sojitra ST; Morisco LL; Burley SK
Trends Pharmacol Sci; 2012 May; 33(5):261-7. PubMed ID: 22521107
[TBL] [Abstract][Full Text] [Related]
18. Advanced beamline automation for biological crystallography experiments.
Cork C; O'Neill J; Taylor J; Earnest T
Acta Crystallogr D Biol Crystallogr; 2006 Aug; 62(Pt 8):852-8. PubMed ID: 16855300
[TBL] [Abstract][Full Text] [Related]
19. Crystallographic fragment screening.
Badger J
Methods Mol Biol; 2012; 841():161-77. PubMed ID: 22222452
[TBL] [Abstract][Full Text] [Related]
20. Perspectives on Fragment-based Drug Discovery: A Strategy Applicable to Diverse Targets.
Li Q; Kang C
Curr Top Med Chem; 2021; 21(13):1099-1112. PubMed ID: 34348623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
